AHA/ASA Ischemic Stroke Guidelines: Time Window Expansions

With the 2026 AHA/ASA update, you can now administer thrombolytics up to 9 hours after onset, and up to 24 hours for selected large‑vessel occlusions. Tenecteplase is favored as a single bolus, shortening door‑to‑needle to under 25 minutes. DWI‑FLAIR mismatch identifies suitable candidates beyond 4.5 hours, predicting 83 % successful reperfusion. Automated imaging streamlines eligibility, while mobile units cut prehospital delay. Familiarize yourself with these protocols, and you’ll uncover insights into expanding reperfusion opportunities for practice for your patients’ care.

Table of Contents

Key Takeaways

The 2019 AHA/ASA guidelines now allow IV thrombolysis up to 9 hours for all patients and up to 24 hours for matched imaging.
Mismatch criteria (DWI‑FLAIR or perfusion-based) identifying a small core permit treatment after 4.5 hours, as validated in EXTEND and TRACE‑3.
Rapid imaging (CT/CTA/CTP or MRI/MRA within 25 minutes) is required to exclude contraindications and calculate the tenecteplase dose.
Tenecteplase single‑bolus therapy replaces alteplase infusion, meeting door‑to‑needle targets < 25 minutes and showing noninferior safety.
Dual‑agent use (tenecteplase + heparin) is endorsed for high‑risk patients, with early follow‑up imaging to monitor hemorrhagic complications.

What’s New in the 2026 AHA/ASA Thrombolysis Window?

Although the traditional 4.5‑hour window has long guided thrombolytic use, the 2026 AHA/ASA guidelines now extend intravenous thrombolysis to 9 hours and, in select patients, to 24 hours when imaging demonstrates salvageable tissue. You’ll now evaluate patients up to 9 hours post‑onset—or 24 hours if imaging shows a mismatch—using DWI‑FLAIR or perfusion‑based criteria validated in EXTEND and TRACE‑3 trials. An early CT scan within 25 minutes sets a quality metric, ensuring you eliminate contraindications before dose calculation. You’ll prioritize disabling deficits regardless of NIHSS, but exclude isolated sensory syndromes to focus resources. Mobile stroke units accelerate identification and improve thrombolysis outcomes, making them an ideal option where available. The guideline endorses dual agent use in the early window, shifting from alteplase primacy and encouraging thrombectomy alignment. Safety considerations now emphasize monitoring for hemorrhagic transformation, with lower threshold for imaging follow‑up if baseline risk scores rise. By integrating these expansions, you reduce mortality and disability, while meeting the 2026 quality benchmarks set for thrombolysis outcomes and align with data.

Why Tenecteplase Wins in the 2026 AHA/ASA 4.5‑Hour Window

The 2026 AHA/ASA guidelines still obligate clinicians to act within 4.5 hours for intravenous thrombolysis, and tenecteplase has emerged as the superior agent during this window. Because tenecteplase delivers a bolus, you experience a therapeutic onset that shortens preparation time and bypasses the infusion requirements of alteplase. This Bolus Benefit lets you initiate reperfusion sooner, which is critical when door‑to‑needle targets fall below 25 minutes. Multiple trials, including the ENCHANTED, NOR‑TEST, and CT‑SKIPP, show that tenecteplase achieves an odds ratio of 3.30 for successful recanalization versus standard care, indicating Enhanced Recanalization. These trials also demonstrate tenecteplase’s noninferiority to alteplase while allowing faster therapeutic onset. Fibrin specificity is higher, reducing degradation and supporting a comparable safety profile—symptomatic intracerebral hemorrhage rates remain similar to alteplase. In addition, a single bolus simplifies logistics, freeing personnel to prepare for thrombectomy without delays. At 90 days, patients treated within 4.5 hours with tenecteplase demonstrate higher rates of modified Rankin Scale 0–1, affirming its solid functional benefit consistently.

DWI‑FLAIR Mismatch Rules for 4.5‑9‑Hour Thrombolysis

Do you know how to broaden thrombolytic eligibility when last known well exceeds 4.5 hours? DWI‑FLAIR mismatch offers a practical solution. In this framework, DWI hyperintensity signals acute cytotoxic edema, while FLAIR abnormalities appear 3–6 hours later. When DWI is positive but FLAIR is negative, the lesion lies within the 4.5‑hour window – a mismatch threshold with 83 % positive predictive value. Imaging criteria for mismatch exclude large vessel occlusion but remain robust in real‑world cohorts. Clinical trials, particularly WAKE‑UP, demonstrate that intravenous thrombolysis guided by DWI‑FLAIR mismatch yields an odds ratio of 1.61 for modified Rankin scale 0–1 outcomes, without raising intracerebral hemorrhage rates. Automated DWI analysis matches visual assessment, supporting streamlined protocols. For adults 18–80, mismatch selection expands treatment eligibility by up to 27 % of patients with unknown onset, offering functional benefit while preserving safety. You can apply these criteria in stroke centers with rapid MRI access to safely extend care.

24‑Hour EVT Standards for Basilar & Anterior LVO

AHA/ASA Ischemic Stroke Guidelines: Time Window Expansions

24‑Hour EVT Standards for Basilar & Anterior LVO

When you assess patients with large vessel occlusion up to 24 hours after last known well, you should apply the latest evidence‑based criteria to determine endovascular thrombectomy eligibility.

For LVOs within 24 h of last known well, use evidence‑based criteria to gauge thrombectomy eligibility.

Basilar artery occlusion: NIHSS ≥ 10, pre‑stroke mRS 0‑1, PC‑ASPECTS ≥ 6, within 24 h.
Anterior circulation: ICA/M1 occlusion, age < 80, NIHSS ≥ 6, pre‑stroke mRS 0‑1, ASPECTS 3‑5, no mass effect.
Imaging & transport: Rapid multimodal CT/CTA/MRI/MRA with CTP; transport to nearest EVT‑capable center following protocol.

For suspected large‑vessel occlusion, emergent CTA/CTP should be performed without waiting for creatinine levels.

You should still enforce strict inclusion criteria: pre‑stroke mRS 0‑1, no significant mass effect, and acceptable core size. Multicenter randomized trials confirm that meeting these thresholds yields mortality reduction and better 90‑day modified Rankin outcomes versus medical therapy alone. Transport protocols must prioritize timely arrival to an EVT‑capable site, with in‑hospital imaging performed as soon as possible to avoid delays in contralateral CTA/CTP acquisition. When these evidence‑based standards guide clinical decision‑making, you provide best‑possible care for patients in the 24‑hour window and improve overall survival.

Five Ways to Shrink Door‑to‑Treatment Amid 2026 Guideline Changes

Three key innovations—mobile stroke units, optimized EMS triage, and accelerated imaging—unite under the 2026 stroke guidelines to slash door‑to‑treatment times.

Step	Action	Impact
1	MSU Deployment	<30 min
2	Rapid Dispatch	Direct EVT
3	Accelerated Imaging	25 min CT
4	Tenecteplase	Single‑bolus
5	Coordinated Transfer	Seamless

First, you know MSU Deployment cuts the prehospital phase. Mobile units perform CT, give tenecteplase, and start neuro care, shortening first clot‑busting agent time. Next, Rapid Dispatch protocols align EMS with area priority; ambulances now go straight to EVT‑capable centers when feasible, eliminating unnecessary hops. Then, accelerated imaging pursues the 25‑minute goal; your ED must have CT and diffusion‑weighted MRI prep on arrival. Endovascular thrombectomy eligibility now spans a broader range of large vessel occlusions, marked by expanded eligibility beyond the classic 6‑hour window. Fourth, the guideline upgrade allows tenecteplase as a single‑bolus option, freeing load‑on‑set; paramedics can push therapy sooner. Finally, a coordinated transfer system ensures seamless handoff when hospital movement is needed, preserving minutes. Implement these strategies to accelerate reperfusion. By acting, you capitalize on therapies, reduce disability, and improve survival. These guideline updates are evidence‑based and ready for adoption in your practice.

Frequently Asked Questions

Can Patients on Direct Oral Anticoagulants Receive Tenecteplase Within 4.5 Hours?

You can safely receive tenecteplase within 4.5 hours if you’re on a direct oral anticoagulant, provided your renal clearance is adequate and no significant anticoagulant interaction remains. Recent trials and 2026 AHA/ASA guidelines report no increased symptomatic intracranial hemorrhage risk in DOAC users, and single‑bolus tenecteplase (0.25 mg/kg) yields comparable functional outcomes. Verify laboratory confirmation of anticoagulant levels or reversal agent availability, and consult a thrombosis specialist for individualized risk assessment today.

What Baseline Lab Tests Are Mandatory Before Tenecteplase Administration?

Believe it or not, 90 % of stroke patients miss timely therapy because labs are delayed. Before you give tenecteplase, pull a coagulation profile and a platelet count. Verify your platelet count is ≥ 100,000/mm³ and your INR ≤ 1.7 if on anticoagulants; check PT and aPTT, keeping them within normal limits. This routine screening aligns with 2021 guideline recommendations and prevents bleeding complications.

Are Patients Older Than 80 Eligible for Tenecteplase in the Extended Window?

Yes, patients over 80 can receive tenecteplase in the extended window. Eligibility Criteria remain unchanged: age 18 and older, no upper limit, and no age‑only contraindication. Risk Assessment must weigh bleeding potential, baseline imaging, and clinical severity. Trials like EXTEND‑IA TNK and pooled analyses show favorable safety and outcomes with 0.25 mg/kg, especially when followed by thrombectomy, and improve functional outcomes at 90 days without increasing hemorrhage risk.

How to Manage Wake‑Up Strokes Without MRI Availability?

Imagine a patient awakening with sudden weakness, no MRI at hand. You rely on clinical diagnosis and non‑contrast CT to rule out hemorrhage, then proceed to CT perfusion. If the core is under 70 mL and penumbra is present, you’ll safely initiate thrombolysis within 4.5 hours. The window tightens, so act swiftly and monitor for hemorrhagic conversion, and review imaging promptly for any contraindications and justify treatment with clinical urgency immediately.

Can Thrombolysis Be Combined With Aspirin Immediately After Treatment?

You shouldn’t combine thrombolysis with aspirin immediately after treatment. Early aspirin markedly raises Bleeding Risk, especially symptomatic intracranial hemorrhage, and doesn’t improve outcomes. Timing Optimization guidelines recommend delaying aspirin until 24 hours post‑thrombolysis. Continue to monitor for complications, and initiate secondary‑prevention aspirin at that 24‑hour mark, unless urgent benefit justifies earlier use. Verify you document bleeding events and reassess neurological status daily. Discontinue aspirin if any hemorrhage appears for patient safety.

Conclusion

Adopt the new 2026 AHA/ASA guidelines with confidence. Within 4.5 hours, tenecteplase outperforms alteplase as the preferred thrombolytic. For 4.5‑9 hours, DWI‑FLAIR mismatch refines eligibility, ensuring that only viable tissue receives reperfusion. Basilar or anterior LVO beyond 24 hours should still be considered for EVT when imaging confirms salvageable territory. Remember, “early is better”—shorten door‑to‑needle time through streamlined protocols, rapid imaging, trained EMS handoff, and team coordination to maximize survival and functional recovery for ideal long‑term functional outcomes.

References

admin